Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

被引：30
作者：
Ghazanfar, Misbah Nasheela [1 ]
Thomsen, Simon Francis [1 ]
机构：
[1] Bispebjerg Hosp, Dept Dermatol, D-2400 Copenhagen, NV, Denmark
来源：
CASE REPORTS IN MEDICINE | 2015年 / 2015卷
关键词：
D O I：
10.1155/2015/368053
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria. Several randomised controlled trials have investigated the safety, tolerability, and efficacy of omalizumab for chronic urticaria. The safety of omalizumab in pregnancy is not known. We describe a female patient with chronic spontaneous urticaria who was treated with omalizumab continuously through two consecutive pregnancies with convincing results and no apparent toxicity.
引用
收藏
页数：3
相关论文
共 9 条
[1]   Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy [J].
Kaplan, Allen ;
Ledford, Dennis ;
Ashby, Mark ;
Canvin, Janice ;
Zazzali, James L. ;
Conner, Edward ;
Veith, Joachim ;
Kamath, Nikhil ;
Staubach, Petra ;
Jakob, Thilo ;
Stirling, Robert G. ;
Kuna, Piotr ;
Berger, William ;
Maurer, Marcus ;
Rosen, Karin .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (01) :101-109
[2]   Treatment of chronic autoimmune urticaria with omalizumab [J].
Kaplan, Allen P. ;
Joseph, Kusumam ;
Maykut, Robert J. ;
Geba, Gregory P. ;
Zeldin, Robert K. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (03) :569-573
[3]   Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria [J].
Maurer, Marcus ;
Rosen, Karin ;
Hsieh, Hsin-Ju ;
Saini, Sarbjit ;
Grattan, Clive ;
Gimenez-Arnau, Ana ;
Agarwal, Sunil ;
Doyle, Ramona ;
Canvin, Janice ;
Kaplan, Allen ;
Casale, Thomas .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (10) :924-935
[4]   Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase [J].
Maurer, Marcus ;
Altrichter, Sabine ;
Bieber, Thomas ;
Biedermann, Tilo ;
Braeutigam, Matthias ;
Seyfried, Stefan ;
Brehler, Randolf ;
Grabbe, Juergen ;
Hunzelmann, Nicolas ;
Jakob, Thilo ;
Jung, Andreas ;
Kleine-Tebbe, Joerg ;
Mempel, Martin ;
Meurer, Michael ;
Reich, Kristian ;
Rueff, Franziska ;
Schaekel, Knut ;
Sengupta, Kaushik ;
Sieder, Christian ;
Simon, Jan C. ;
Wedi, Bettina ;
Zuberbier, Torsten ;
Mahler, Vera ;
Staubach, Petra .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (01) :202-U326
[5]  
Namazy J., 2014, J ALLERGY CLIN IMMUN
[6]  
Saini S. S., 2014, J INVESTIGATIVE DERM
[7]   A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria [J].
Saini, Sarbjit ;
Rosen, Karin E. ;
Hsieh, Hsin-Ju ;
Wong, Dennis A. ;
Conner, Edward ;
Kaplan, Allen ;
Spector, Sheldon ;
Maurer, Marcus .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (03) :567-U195
[8]   Effects of omalizumab in a patient with three types of chronic urticaria [J].
Vieira dos Santos, R. ;
Locks Bidese, B. ;
Rabello de Souza, J. ;
Maurer, M. .
BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) :469-471
[9]   The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update [J].
Zuberbier, T. ;
Aberer, W. ;
Asero, R. ;
Bindslev-Jensen, C. ;
Brzoza, Z. ;
Canonica, G. W. ;
Church, M. K. ;
Ensina, L. F. ;
Gimenez-Arnau, A. ;
Godse, K. ;
Goncalo, M. ;
Grattan, C. ;
Hebert, J. ;
Hide, M. ;
Kaplan, A. ;
Kapp, A. ;
Latiff, A. H. Abdul ;
Mathelier-Fusade, P. ;
Metz, M. ;
Nast, A. ;
Saini, S. S. ;
Sanchez-Borges, M. ;
Schmid-Grendelmeier, P. ;
Simons, F. E. R. ;
Staubach, P. ;
Sussman, G. ;
Toubi, E. ;
Vena, G. A. ;
Wedi, B. ;
Zhu, X. J. ;
Maurer, M. .
ALLERGY, 2014, 69 (07) :868-887
1